Showing results (21-30 of 53) with videos related to
Sort By:
Pageof 6
European Journal of Immunology|March 5, 2003
Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cellsJoanne C Cooper, Geoffrey Morgan, Susanne Harding, et al.The AAPS Journal|April 27, 2013
Pre-existing biotherapeutic-reactive antibodies: survey results within the American Association of Pharmaceutical ScientistsLi Xue, Michele Fiscella, Manoj Rajadhyaksha, et al.Journal of Pharmacokinetics and Pharmacodynamics|March 3, 2017
Exposure-disease response analysis of natalizumab in subjects with multiple sclerosisKumar Kandadi Muralidharan, Deb Steiner, Diogo Amarante, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 23, 2011
Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasmaTatiana Plavina, Melissa Berman, Moses Njenga, et al.Journal of Pharmaceutical and Biomedical Analysis|May 3, 2011
Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeuticsShalini Gupta, Viswanath Devanarayan, Deborah Finco, et al.Annals of Neurology|October 3, 2014
Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathyTatiana Plavina, Meena Subramanyam, Gary Bloomgren, et al.Multiple Sclerosis and Related Disorders|January 21, 2017
Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic studyTakahiko Saida, Jun-Ichi Kira, Shuji Kishida, et al.Therapeutic Advances in Neurological Disorders|July 2, 2016
Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trialJoleen T White, Scott D Newsome, Bernd C Kieseier, et al.Plos One|November 27, 2013
Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosisKeith R Edwards, Jaya Goyal, Tatiana Plavina, et al.The New England Journal of Medicine|May 18, 2012
Risk of natalizumab-associated progressive multifocal leukoencephalopathyGary Bloomgren, Sandra Richman, Christophe Hotermans, et al.Pageof 6